Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.69 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.64 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | IDE | P14735 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27233233 | 1.00 | TDP1 (0.69) | TDP1FOLH1CAPN1CA12CA1 | |
| SCHEMBL29928558 | 0.94 | TDP1 (0.75) | TDP1FOLH1CAPN1CA12CA1 | |
| SCHEMBL9807479 | 0.90 | TDP1 (0.77) | TDP1FOLH1CAPN1CA12CA1 | |
| SCHEMBL10044328 | 0.89 | TDP1 (0.72) | TDP1FOLH1CAPN1CA12CA1 | |
| SCHEMBL12809811 | 0.88 | TDP1 (0.73) | TDP1FOLH1CAPN1CA12CA1 | |
| SCHEMBL10308270 | 0.85 | TDP1 (0.74) | TDP1FOLH1CAPN1CA12CA1 | |
| SCHEMBL21110496 | 0.85 | TDP1 (0.51) | TDP1FOLH1CAPN1CNR1 | |
| SCHEMBL29744917 | 0.85 | TDP1 (0.62) | TDP1FOLH1CAPN1CA12CA1 | |
| SCHEMBL13227941 | 0.84 | TDP1 (0.67) | TDP1FOLH1CAPN1CA12CA1 | |
| SCHEMBL29512013 | 0.84 | TDP1 (0.63) | TDP1FOLH1CAPN1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12252705-B2 | Small type II-D Cas proteins and methods of use thereof | THE BROAD INSTITUTE, INC. (US) | 2025-03-18 | — | — | US | disclosed |
| US-12227742-B2 | Nucleic acid modifiers | THE BROAD INSTITUTE, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20240409524-A1 | COMPOUND HAVING PHOTOCLEAVABLE MOIETY, CONJUGATE, AND SCREENING METHOD USING SAME | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-12-12 | — | — | US | disclosed |
| EP-4378944-A1 | COMPOUND HAVING PHOTOCLEAVABLE SITE, LINKER, AND SCREENING METHOD USING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-06-05 | — | — | EP | disclosed |
| CN-117980308-A | Compound having photocleavable site, joined body, and screening method using same | 中外制药株式会社 | 2024-05-03 | — | — | CN | disclosed |
| US-20240026382-A1 | SMALL TYPE II-D CAS PROTEINS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-01-25 | — | — | US | disclosed |
| US-20230340537-A1 | SMALL TYPE II-D CAS PROTEINS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-10-26 | — | — | US | disclosed |
| WO-2023054636-A1 | COMPOUND HAVING PHOTOCLEAVABLE SITE, LINKER, AND SCREENING METHOD USING SAME | 中外製薬株式会社 | 2023-04-06 | — | — | WO | disclosed |
| US-20230091690-A1 | GUIDED EXCISION-TRANSPOSITION SYSTEMS | THE BROAD INSTITUTE, INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230037794-A1 | PROGRAMMABLE DNA NUCLEASE-ASSOCIATED LIGASE AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20220162649-A1 | NOVEL NUCLEIC ACID MODIFIERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| US-20220098620-A1 | NOVEL NUCLEIC ACID MODIFIERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409524-A1 | COMPOUND HAVING PHOTOCLEAVABLE MOIETY, CONJUGATE, AND SCREENING METHOD USING SAME | ALDH1A2, FOLH1, TACR1 | TDP1 3353/4885FOLH1 2/4885CAPN1 2886/4885 |
| US-12227742-B2 | Nucleic acid modifiers | DCLRE1A, MRE11, DDB1 | TDP1 71/4885FOLH1 2674/4885CAPN1 4003/4885 |
| US-20220098620-A1 | NOVEL NUCLEIC ACID MODIFIERS | DCLRE1A, MRE11, DDB1 | TDP1 60/4885FOLH1 2812/4885CAPN1 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.